FDA oversight of cell therapy clinical trials.
Where this comes from
- Record sourced from PubMed, PMID 22932219.
- Also identified by DOI 10.1126/scitranslmed.3004131.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The U.S. Food and Drug Administration applies regulatory flexibility to balance benefits and risks to subjects in cell-therapy clinical trials.
Medical subject headings
- Biological Therapy
- Cell Transplantation
- Clinical Trials as Topic
- Government Regulation
- Health Policy
- Patient Safety
- Research Design
- United States Food and Drug Administration